GORE TAG Endoprosthesis for Aortic Aneurysm

This trial examines the long-term effects of the GORE® TAG® Thoracic Branch Endoprosthesis, a device for treating aortic aneurysms (bulging blood vessels in the chest that can burst if untreated). Researchers aim to assess the device's performance in real-world settings over 5 to 10 years. The trial seeks participants who have used or will use this device in specific parts of the aorta, known as Zone 0 or Zone 1. Individuals with an aortic aneurysm treated or to be treated with this device might be suitable for the trial. As an unphased trial, this study offers a unique opportunity to contribute to understanding the device's long-term effectiveness and safety.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that the GORE® TAG® Thoracic Branch Endoprosthesis is generally safe for people. In past studies, this device demonstrated good safety results. For instance, one study found a high success rate of 98.6% for procedures using this device, with side effects occurring in only 7.8% of cases.

Another study on patients with aortic aneurysms found that the device remained safe and effective for up to 12 months after the procedure. This suggests that the treatment is safe for managing aortic aneurysms, which are bulges in the wall of the aorta, the large blood vessel that carries blood from the heart to the rest of the body.

The GORE® TAG® Thoracic Branch Endoprosthesis stands out from current treatments for aortic aneurysms due to its innovative design that specifically targets the thoracic aorta. Unlike traditional open surgical repair or non-branch-specific endografts, this device is designed to accommodate the complex anatomy of the aortic arch, potentially reducing the need for more invasive surgery. Researchers are excited because it offers a minimally invasive option that could lead to quicker recovery times and fewer complications, which is a significant advantage for patients who might not be suitable candidates for conventional surgical procedures.

Research has shown that the GORE® TAG® Thoracic Branch Endoprosthesis, which participants in this trial will receive, effectively treats aortic aneurysms. Studies have found it can safely address issues in the aorta, the main blood vessel from the heart, without increasing complications. Early results suggest it significantly reduces the risk of problems during and after the procedure. Patients using this device have demonstrated good short-term and midterm outcomes, with low rates of failure and complications. Its design ensures a good fit in the aorta, enhancing the treatment of aortic issues like tears and bulges. Overall, it has proven effective for the conditions it targets.⁵⁶⁷⁸⁹